Previous 10 | Next 10 |
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced ...
Aerie Pharmaceuticals, Inc. (AERI) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Ami Bavishi – Director of Investor Relations Vince Anido – Chairman and Chief Executive Officer Tom Mitro – President and Chief Operating Officer Rich Rubi...
Image source: The Motley Fool. Aerie Pharmaceuticals Inc (NASDAQ: AERI) Q3 2020 Earnings Call Nov 6, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Aerie Pharmaceuticals Inc (AERI) Q3 2020 Earnings Call Transcript ...
Aerie Pharmaceuticals, Inc. (AERI) Q3 2020 Earnings Conference Call October 5, 2020 4:50 PM ET Company Participants Ami Bavishi - Director of Investor Relations Vicente Anido - Chairman & Chief Executive Officer Tom Mitro - President & Chief Operating Officer Rich Rubino - Chief Finan...
Aerie Pharmaceuticals (AERI): Q3 Non-GAAP EPS of -$0.65 beats by $0.15; GAAP EPS of -$0.86 beats by $0.10.Revenue of $20.1M (+8.4% Y/Y) beats by $0.64M.Press Release For further details see: Aerie Pharmaceuticals EPS beats by $0.15, beats on revenue
Year-to-Date Net Revenues of $58.5 Million Increased 29% over 2019 Third Quarter Net Revenues of $20.1 Million or $77 Per Bottle U.S. Dry Eye Trial Initiated and Japanese Glaucoma Trial Set to Commence Conference Call and Webcast Today, November 5 th ,...
Heat Biologics boosts patents portfolio with gp96 combination award. Teleflex announces acquisition of hemostatic company Z-Medica. Aerie Pharmaceuticals begins Phase 2b dry eye diseases clinical trial. For further details see: Heat Biologics Provides Update, And Other N...
Aerie Pharmaceuticals (AERI) has commenced COMET-1 Phase 2b trial of AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease.The 360-subject trial will evaluate the efficacy and safety of AR-15512. Patients will receive either AR-15512 0.0014%, AR-15512...
-First Patient Dosed in 90-Day Efficacy Trial Named COMET-1- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle gla...
Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa ® and Rocklatan ® in ...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...